Topical delgocitinib is an efficacious and well tolerated treatment for patients with chronic hand eczema
Worm M, Bauer A, Elsner P, Mahler V, Molin S, Nielsen TSS (2019)
Publication Type: Conference contribution
Publication year: 2019
Journal
Publisher: MOSBY-ELSEVIER
City/Town: NEW YORK
Pages Range: AB138-AB138
Conference Proceedings Title: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Event location: Washington, DC
DOI: 10.1016/j.jaad.2019.06.519
Authors with CRIS profile
Additional Organisation(s)
Involved external institutions
Technische Universität Dresden
Germany (DE)
LEO Pharma A.S.
Denmark (DK)
Friedrich-Schiller-Universität Jena
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Queen's University
United Kingdom (GB)
Germany (DE)
LEO Pharma A.S.
Denmark (DK)
Friedrich-Schiller-Universität Jena
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Queen's University
United Kingdom (GB)
How to cite
APA:
Worm, M., Bauer, A., Elsner, P., Mahler, V., Molin, S., & Nielsen, T.S.S. (2019). Topical delgocitinib is an efficacious and well tolerated treatment for patients with chronic hand eczema. In JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (pp. AB138-AB138). Washington, DC, US: NEW YORK: MOSBY-ELSEVIER.
MLA:
Worm, Margitta, et al. "Topical delgocitinib is an efficacious and well tolerated treatment for patients with chronic hand eczema." Proceedings of the Annual Meeting of the American-Academy-of-Dermatology (AAD), Washington, DC NEW YORK: MOSBY-ELSEVIER, 2019. AB138-AB138.
BibTeX: Download